38 results about "Intragastric administration" patented technology

The application provides a starch-indole acid derivative and a preparation method and application thereof, and relates to the technical field of modified starches. The starch-indole acid derivative refers to esterified starch generated by esterification reaction of starch, a condensing agent and alkali and indole acid. The starch-indole acid derivative has high resistance and can resist degradation of the stomach and small intestine. After reaching the colon site, the starch-indole acid derivative can be fermented by intestinal flora to release indole acid beneficial to intestinal health. Compared with traditional drug delivery modes such as intragastric administration and intraperitoneal injection, the starch-indole acid derivative has obvious advantages and can significantly increase the content of indole acid in the colon and hepatic portal vein blood. In addition, indole acid can activate an aromatic hydrocarbon receptor to play an immunoregulatory role. The immunoregulatory role of indole acid is superimposed on the regulation role of short-chain fatty acids released by starch fermentation by intestinal flora, so that a product playing an immunoregulatory role through multiple immune system signal pathways is provided.

The invention relates to genetic engineering combined lactobacillus salivarius and application of the genetic engineering combined lactobacillus salivarius. The strain is classified and named as combined lactobacillus salivarius CTMT2, and the preservation number of the strain is CCTCC (China Center for Type Culture Collection) M 2025547. After an NIAAA model is injected into the stomach of an alcoholic liver mouse, the acetaldehyde level of the liver of the mouse is obviously reduced, and the alcoholic fatty liver symptom of the mouse is obviously relieved; after long-term intragastric administration of a high-glucose and high-fat modeling mouse, the acetaldehyde level in excrement of the mouse can be obviously reduced, the progress of liver fibrosis is improved, and good application prospects are achieved.

The invention belongs to the technical field of animal model construction, and particularly provides a construction method and application of a mouse non-alcoholic fatty liver model, and the construction method comprises the following steps: S1, selecting an experimental mouse; s2, a high nitrogen compound aqueous solution with the mass concentration of 4-10 mg / mL is prepared; s3, according to the dosage, the dosage and the administration time, the prepared high-nitrogen compound aqueous solution is fed through the intragastric administration, and the non-alcoholic fatty liver animal model is obtained, the problems that an existing non-alcoholic fatty liver animal model is long in modeling time and expensive in modeling are solved, and the non-alcoholic fatty liver animal model does not need to be fed with high-fat feed, and is simple, convenient and feasible, low in cost, good in repeatability and stable; the establishment period of the non-alcoholic fatty liver animal model can be effectively shortened, the time cost of the medical research of the NAFLD is greatly saved, and a good animal model is provided for researching the pathogenesis and treatment strategy of the NAFLD.

The invention discloses a preparation method for constructing a mouse embryo implantation failure model based on fusobacterium variabilis, and belongs to the technical field of animal models. The method comprises the following steps: carrying out anaerobic culture on fusobacterium varium, giving the fusobacterium varium to a female C57 mouse through an intragastric administration way, continuously treating for 28 days, and inducing the female C57 mouse to have a phenotype that the number of implanted embryos is reduced and the expression of a vascular endothelial growth factor (VEGF) in a uterine tissue is reduced. According to the method, embryo implantation failure caused by intestinal flora imbalance is simulated through the'intestine-uterus axis' for the first time, a reliable animal model is provided for studying the causal relationship between flora and pregnancy failure, and the method has important scientific research and clinical application value.

The present application provides a probiotic compound preparation, which is prepared by directly mixing a probiotic compound colony dry powder with inorganic material, wherein the inorganic material is inorganic mineral material subjected to dispersion treatment; and provides a preparation method and application thereof.The probiotic compound preparation provided by the present application can play a role through simple methods such as oral administration and intragastric administration.The inorganic mineral material subjected to dispersion treatment can effectively improve its carrying capacity and colonization capacity, and can also change the microenvironment in the host body through the inorganic mineral material itself, so as to achieve the purpose of changing the composition and quantity of intestinal microflora, and then through the change of the composition and quantity of intestinal microflora, the purpose of preventing, relieving and treating various diseases caused by intestinal flora imbalance can be achieved.

The invention discloses an application of isolithocholic acid in preparation of a medicine for preventing or treating colorectal cancer induced by high fat diet. The invention proves that the isolithocholic acid can be accurately replenished by intragastric administration of 100g / kg of isoLCA at one time, and meanwhile, the isolithocholic acid can obviously inhibit the occurrence of obesity-related colon tumors, reduce the proliferation index of tumor cells and repair the intestinal barrier structure. Isolithocholic acid is endogenous secondary bile acid, can be chemically synthesized or semi-synthesized, is high in safety and good in patient compliance through oral administration, is expected to reduce the occurrence rate of colorectal cancer of obese people, and has important significance in treatment of colorectal cancer.

The invention discloses a bacterial infection and LPS induced broiler chicken liver injury model and a construction method and application thereof, and the construction method comprises the following steps: administering 10-day-old broiler chicken with Escherichia coli E.coli O78 with a preset concentration in an intragastric administration manner; after broiler chickens are subjected to intragastric administration of escherichia coli for 18 hours, an LPS solution is injected into the intraperitoneal cavity of the broiler chickens, after the LPS solution is injected for 24 hours, the broiler chicken liver injury model is obtained, when the broiler chickens are 11 days old, the broiler chickens subjected to intragastric administration of escherichia coli are subjected to intraperitoneal injection of the LPS solution, and after the LPS solution is injected for 24 hours, the broiler chicken liver injury model is obtained. The broiler chicken liver injury model is constructed by intragastric administration of avian pathogenic escherichia coli (E.coli O78) and intraperitoneal injection of LPS (2 mg / kg), the pathology of the model is highly consistent with that of clinical broiler chicken bacterial liver injury, the liver has clinical typical lesions macroscopically, liver cells are degenerative and necrotic microscopically, and a molecular pathway activation mode is consistent with that of clinical application; the model constructed by the invention realizes specific liver injury, only the liver has specific injury, multiple organ lesions such as heart, peritoneum and the like do not exist, and the model availability is high.

The invention relates to application of a horseradish tree leaf extract in preparation of fat-reducing medicines or functional foods, and belongs to the technical field of medicines. The application comprises the following steps that S1, mice are evenly divided into five groups according to the weight of the mice after being fed for one week under the conditions of constant temperature and humidity, each group comprises eight mice, and the five groups comprise a normal control Con group, a high-fat and high-cholesterol HFC model group, a low-dose moringa oleifera leaf extract L-MOL intervention group, a high-dose moringa oleifera leaf extract H-MOL intervention group and a positive drug rosiglitazone RSG intervention group; s2, except the normal control Con group, high-fat feed is administered to other groups, administration is performed in an intragastric administration mode at ten o'clock in the morning every day, the weight of the mice is observed and recorded, and continuous administration is performed for 60 days; s3, stopping taking medicine for 24 hours after the step S2, anesthetizing and sampling blood, dissecting after cervical vertebra dislocation and killing, dissecting the abdomen of the mouse, taking a picture, and recording the subcutaneous fat weight and the white fat weight of the abdomen of each group of mouse. The moringa oleifera leaf extract provided by the invention shows an excellent fat reducing effect.

The invention discloses a group of immunogenic peptides with an anti-tumor immune response activating function as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The amino acid sequences of the immunogenic peptide are SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4, and the immunogenic peptide is obtained by the following steps: extracting an enterovirus-like particle (VLPs) preparation from excrement of a healthy mouse, giving the preparation to a tumor model mouse through intragastric administration, and separating and screening from ileum tissues of the mouse by using a liquid chromatography-mass spectrometry technology. The VLPs can be migrated to tumor tissues and presented as the immunogenic peptide through tumor cell MHC-I molecules, so that CD8 + T cells are efficiently activated, a tumor immune microenvironment is remodeled, and tumor growth is inhibited. Experiments show that the immunogenic peptide shows a remarkable anti-tumor effect when being used alone or combined with a PD-1 inhibitor, and the tumor inhibition rate of drug combination can reach 89.4% and is remarkably superior to that of single treatment.

The present application belongs to the technical field of animal model construction, and relates to a insomnia animal model construction method and application with the characteristics of body deficiency, fever and emotional irritability. The application of uncoupling agent as a modeling agent in the construction of insomnia animal model with the characteristics of body deficiency, fever and emotional irritability; the uncoupling agent is carbonic acid cyanide-4-trifluoromethoxy benzyl hydrazone, carbonyl cyanide m-chlorophenyl hydrazone or benzalazoline. The present application uses mice as model animals, uses uncoupling agent as a modeling agent, and suspends or dissolves the modeling agent, then gives the mice intragastric administration once a day, and lasts for 1-4 weeks, to construct a "deficiency and irritability insomnia" insomnia animal model with the characteristics of body deficiency, fever and emotional irritability. The present application has a high degree of consistency with the traditional Chinese medicine theory, and can be well used for the screening and evaluation of anti-insomnia chemical drugs, anti-insomnia traditional Chinese medicine compounds and anti-insomnia health care products.

The invention relates to the field of medicines, and particularly discloses application of bile acid in preparation of a medicine for treating osteoporosis. Research finds that the content of hyodeoxycholic acid (HDCA) in an old individual is remarkably reduced, and the bone mineral density and the bone microstructure can be improved by supplementing the HDCA. Animal experiment results show that the HDCA can significantly inhibit bone mass loss and improve bone quality through oral administration and intragastric administration, and the effect of the HDCA depends on a bile acid receptor TGR5. HDCA is provided as an active component for treating osteoporosis for the first time, and a new drug candidate and an action mechanism can be provided for prevention and treatment of osteoporosis.

The present invention provides methods for increasing the systemic bioavailability of a polypeptide therapeutic administered orally, via oral gavage, via nasogastric gavage, or intragastric administration, comprising administering the polypeptide therapeutic to the stomach of a human or non-human animal as part of one or more dosage forms together with an alginate oligomer and, optionally, a gastrointestinal permeation enhancer, wherein the one or more dosage forms do not, in addition to the polypeptide therapeutic, the alginate oligomer, and, if used, the gastrointestinal permeation enhancer, have a coating that provides substantial protection from the gastric environment. Such methods allow for the systemic treatment or prevention of diseases, conditions, or complications thereof that are responsive to or prevented by the polypeptide therapeutic via oral, oral gavage, via nasogastric gavage, or intragastric administration. Further provided are compositions comprising an alginate oligomer, a polypeptide therapeutic, and, optionally, a gastrointestinal permeation enhancer for use in such methods.

The invention belongs to the field of medicine and health, and particularly relates to application of fresh traditional Chinese medicine radix puerariae exosome-shaped vesicles P-ELNs in medicine or health food for preventing and treating irritable bowel syndrome, the P-ELNs serving as an active ingredient can improve expression of colonic intestinal mucus protein MUC2 and tight junction protein ZO-1 and improve mucous membrane barrier integrity; the inhibition of the expression level of proinflammatory factors (such as TNF-alpha, IL-6, IL-1beta and NF-kappa B) indicates that the action mechanism may involve the synergistic effect of inflammation inhibition and barrier repair. Toxicological experiments show that the P-ELNs have no toxicity after long-term intragastric administration, have no adverse effects on heart, liver, spleen, lung and kidney functions, and have good oral safety and tissue tolerance. The indications comprise anti-inflammatory treatment of active-stage UC patients; maintenance and barrier repair of patients in the UC remission period; the UC disease course is more than or equal to 8 years, and a preventive medicine is applied to high-risk people with cancerization family history and the like; the invention relates to auxiliary treatment of UC-CAC early cancerization patients.

The invention belongs to the technical field of animal model establishment, and discloses an establishment method and application of a chronic oral ferric citrate induced Parkinson mouse model, C57BL / 6 mice are fed with mouse maintenance food (high-iron feed) added with 2.25% ferric citrate for 22 weeks, and then a 5% ferric citrate solution is used for intragastric administration for 4 weeks. Finally, behavioral evaluation is carried out through behavioral tests such as an open field test, a rotating rod test, a pole climbing test, a holding power test and a Y labyrinth test, and the tests such as the rotating rod test, the pole climbing test and the holding power test show that the PD model mouse has remarkable motor function impairment such as reduction of motor coordination, muscular tension and balance force; open field tests and Y maze show that learning and memory functions of mice are impaired, and cognitive impairments such as anxiety mood occur. Clinical chronic disease conditions of Parkinson's disease are simulated, and the chronic model is more suitable for monitoring early changes and screening early diagnosis indexes of Parkinson's disease; the method has the characteristics that the behavioral disorder can be quantified, and DA energy neuron degeneration loss characteristic lesion is realized.

The invention discloses a construction method and application of a fetal ovarian reserve function reduction animal model based on an HDAC1 / USP9X pathway. According to the fetal-derived ovarian reserve function reduction model, 20 mg / kg of aspirin is given to rodents (such as Kunming mice) through intragastric administration in 9-18 days of pregnancy, and typical ovarian reserve function reduction occurs after female offspring birth. Based on an in-vitro cultured fetal ovarian model, the disintegration of germ cell nests and the assembly of primordial follicles can be improved by treating with an HDAC1 specific inhibitor Pyroxamide, and the injury caused by aspirin can be reversed. Therefore, the animal model established by the invention is novel, reliable, simple and convenient, meanwhile, the Pyroxamide has the effect of improving the reduction of the ovarian reserve function, and a new way is provided for preventing and treating the reduction of the fetal ovarian reserve function.

The invention belongs to the technical field of biological medicine, and relates to a thyroid-associated ophthalmopathy animal model construction method, which comprises: after constructing a pseudo-sterile animal model, firstly performing intragastric administration on the pseudo-sterile animal model with a coprophilous bacteria liquid of a thyroid-associated ophthalmopathy mild patient in a first stage, and injecting Ad-TSHR once in the latter half of the first stage; lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, then in the third stage, the faecal bacteria liquid of the patient with the severe thyroid-associated eye disease is injected into the pseudo-sterile animal model, and Ad-TSHR is injected once in the second half process of the third stage; finally, Ad-TSHR is injected once in the latter half of the fourth stage; and obtaining the thyroid-associated eye disease animal model. Under the condition that the number of immunization times of the model is less, the morbidity of the model reaches up to 80%, and the death rate of the model is remarkably reduced.

The invention discloses application of Pediococcus pentosaceus PPSJ001 or peptidoglycan of the Pediococcus pentosaceus PPSJ001 in preparation of a product for preventing or treating intestinal inflammatory diseases, and the Pediococcus pentosaceus PPSJ001 is Pediococcus pentosaceus. The invention further discloses a preparation method of the Pediococcus pentosaceus PPSJ001 and a preparation method of the Pediococcus pentosaceus PPSJ001. According to the application research of the pediococcus pentosaceus PPSJ001 and peptidoglycan thereof in DSS-induced acute and chronic colitis mouse models, prophylactic or therapeutic gavage can obviously reduce the inflammation degree, relieve weight loss, restore the colon length and improve pathological damage of colon tissue. The pediococcus pentosaceus PPSJ001 can be used for promoting the expression of tight junction proteins ZO-1 and Occludin and mucoprotein Muc2 and improving the barrier function of intestinal mucosa. The key functional component is cell wall peptidoglycan, and the peptidoglycan can remarkably relieve the colitis disease in vivo, promote polarization of macrophages to a CD206 + M2 type in vitro and improve expression of anti-inflammatory related genes Arg1. Based on the unique functions, the pediococcus pentosaceus PPSJ001 or peptidoglycan thereof can be coordinated or complemented with other micro-ecological regulation means, and has a wide application prospect in medicine preparation.

The application discloses a composition containing auro-thio-logic acid and polysulfide and application thereof, and belongs to the technical field of biological medicines, wherein the composition comprises auro-thio-logic acid and polysulfide. The application solves the defect that auro-thio-logic acid cannot efficiently inhibit cancer cell proliferation under normal physiological conditions by combining auro-thio-logic acid and polysulfide. When combined with polysulfide, auro-thio-logic acid can well inhibit the growth of tumors, indicating that auro-thio-logic acid and polysulfide can be applied as an anticancer drug combination. Moreover, the absorption of auro-thio-logic acid in tumor tissues can be adjusted by adjusting the type of polysulfide, so that the composition has good selectivity in anticancer in vivo. The composition has good stability and is not easy to be oxidized by air. The drug combination can also achieve an anticancer effect by oral (intragastric administration) mode, and is not limited to intraperitoneal or intravenous injection mode. Meanwhile, the drug combination also has good antibacterial effect.

The invention provides a construction method and application of a drug-induced mouse liver cancer model, and the construction method comprises the following steps: step S10, intragastric injection or intraperitoneal injection of a mouse with a DEN aqueous solution for 1-2 weeks, 5 times per week, to obtain a preliminary cancer-induced mouse; and step S20, carrying out tail intravenous injection on the mouse by using the DEN-loaded exosome solution for 4-6 weeks, and carrying out injection for 5 times per week to obtain the hepatocellular carcinoma-inducing mouse model. According to the scheme, firstly, a DEN aqueous solution is injected into a mouse through intragastric administration or intraperitoneal injection, so that the activity and the phagocytic function of liver macrophages are damaged, and the number of peritoneal macrophages is reduced; then, an exosome solution is injected into the caudal vein of the mouse, DEN is loaded in exosomes, when the exosomes enter the circulatory system through the caudal vein, the exosomes firstly flow through the liver to be metabolized, due to the fact that the activity of liver macrophages is invalid, liver cells can absorb the exosomes carrying the DEN, hepatocellular canceration is rapidly induced in the cell metabolism process, and the liver cancer is rapidly induced; and the modeling success rate of the mouse model is improved.

The application belongs to the technical field of medicine, and particularly relates to application of a 4-(4-diethylamino-1-methylbutylamino)-7-chloroquinoline derivative or a pharmaceutically acceptable salt thereof, or a tautomer thereof, or an internal racemate thereof, or an external racemate thereof, or an enantiomer thereof, or a diastereomer thereof, or a pharmaceutical composition with the active ingredient to preparation of a medicine for preventing or treating obesity and obesity-related metabolic diseases. The 4-(4-diethylamino-1-methylbutylamino)-7-chloroquinoline derivative has a significant curative effect on obesity and related metabolic diseases. After intragastric administration of the 4-(4-diethylamino-1-methylbutylamino)-7-chloroquinoline derivative to obese mice induced by high-fat feed and high-fructose drinking water, after 6 weeks, compared with a high-fat control group, the 4-(4-diethylamino-1-methylbutylamino)-7-chloroquinoline derivative inhibits more than 70% of weight gain of the mice, and there is no significant difference in food intake and water intake, and the 4-(4-diethylamino-1-methylbutylamino)-7-chloroquinoline derivative has a good clinical application prospect.

The invention relates to combined lactobacillus salivarius and application thereof, the strain is classified and named as combined lactobacillus salivarius CTMT1, and the preservation number of the strain is CCTCC M 2025546. After an NIAAA model is injected into the stomach of an alcoholic liver mouse, the acetaldehyde level of the liver of the mouse is obviously reduced, and the alcoholic fatty liver symptom of the mouse is obviously relieved; after long-term intragastric administration of a high-glucose and high-fat modeling mouse, the acetaldehyde level in excrement of the mouse can be obviously reduced, the progress of liver fibrosis is improved, and good application prospects are achieved.

This invention provides a mouse model of hypothyroidism combined with pulmonary hypertension, its construction method, and its application, belonging to the field of animal experimental model construction technology. In this invention, a hypothyroid mouse model was obtained by intragastric administration of methimazole and feeding mice under normoxic conditions. The hypothyroid mouse model was then further modified by intragastric administration of methimazole, followed by continuous subcutaneous injection of the vascular endothelial growth factor inhibitor Su5416, and feeding the mice under hypoxic conditions to obtain a mouse model of hypothyroidism combined with pulmonary hypertension. This invention successfully established a stable mouse model of hypothyroidism combined with pulmonary hypertension through a combination of drug intervention and hypoxic feeding.

The application provides a construction method and application of a polycystic ovary syndrome animal model; through a way of intragastric administration, the mouse intestinal tract is transplanted with fusobacterium nucleatum, and through a certain frequency, the fusobacterium nucleatum can be stably planted, and a stable polycystic ovary syndrome symptom is successfully generated; the sex hormone level of the mouse is significantly different from the PCOS characteristic, is shown as the increase of the LH level, the LH / FSH ratio and the T level, and multiple vesicle structures are seen in the ovary, and no mature follicle and corpus luteum are seen, so that the typical symptom of the polycystic ovary syndrome is met, and a new model selection is provided for screening of a treatment drug or experimental research of the polycystic ovary syndrome.

The invention discloses a method for simultaneously increasing the concentration of citalopram hydrobromide and serotonin in the hypothalamus of a rat, the method comprises the step of intragastric administration of citalopram hydrobromide and borneol to the rat, the dosage of citalopram hydrobromide is 2mg / kg, and the dosage of borneol is 30mg / kg. After citalopram hydrobromide and borneol are administered in the stomach, Cmax and AUC0-t of citalopram hydrobromide are remarkably increased, in addition, the ratio of 5-hydroxyindoleacetic acid to 5-hydroxytryptamine is remarkably reduced, and it is indicated that BO can more effectively enhance hypothalamic citalopram hydrobromide and serotonin in hypothalamic of a conscious rat.

The invention discloses a method for researching a mild cognitive impairment action mechanism of a cornu cervi pantotrichum polypeptide based on a Wnt / beta-catenin signal channel, relates to the technical field of mechanism analysis, and solves the problem of difficulty in realizing spanning from basic research to clinical transformation in the prior art. Randomly dividing the rats into five groups of blank control, model, positive control and VAP high / low dose, continuously performing intragastric administration on each group for 18 days, and feeding distilled water into the blank and model groups; 2 mg / kg scopolamine is injected into abdominal cavities of the model group after 18 days and 2 hours, and normal saline is injected into the blank group; the scopolamine model is used for measuring the 2min static / motion time of the rat by using an open field experiment, and the unilateral common carotid artery ligation model is used for measuring the escape latency / platform penetration times by using a water maze; the method comprises the following steps: taking blood, separating a hippocampal region, and carrying out HE dyeing, ELISA and Western blot; sPSS 21.0 analysis and single factor variance analysis are used for evaluating the difference and Plt; 0.05 or Plt; 0.01 has statistical significance.

The invention discloses a construction method and application of a fetal-derived hypercholesterolemia animal model. The fetal-derived hypercholesteremia animal model is characterized in that 20 mg / kg of aspirin with a clinical dose is given to rodents (such as Kunming mice) through oral intragastric administration in the middle and late pregnancy periods (such as 9-18 pregnancy), and typical hypercholesteremia appears after high-fat diet is given to male filial generations 8-12 weeks after the male filial generations are born. Based on mice exposed by aspirin during pregnancy, ascorbic acid is externally supplemented to maternal bodies during pregnancy, so that the liver cholesterol synthesis function and the blood cholesterol level of offspring can be effectively reduced. Therefore, the established fetal hypercholesterolemia animal model has the characteristics of novelty, reliability and simplicity and convenience in operation, meanwhile, the effect of reversing the susceptibility of offspring hypercholesterolemia by supplementing ascorbic acid to the maternal body is found, and a new thought and a new technology are provided for early prevention and treatment of fetal hypercholesterolemia.

Compositions and methods for enhancing the absorption of therapeutic polypeptides from the intestines following oral administration The invention provides a method for increasing the systemic bioavailability of a polypeptide therapeutic agent undergoing oral, orogastric, nasogastric, or intragastric administration, said method comprising administering said polypeptide therapeutic agent together with (i) an alginate oligomer (ii) a compound of Formula (I), or a pharmaceutically acceptable salt thereof, (I) (iii) a compound of Formula (II), or a pharmaceutically acceptable salt thereof, (II) to a portion of the intestines of a human or non-human animal subject by oral, orogastric, nasogastric, or intragastric administration, wherein said portion of the intestines is contacted with (i), (ii), (iii) and said polypeptide therapeutic agent in amounts which result in uptake of the polypeptide therapeutic agent from said portion of the intestine. Such methods allow for systemic treatment or prevention of a disease or condition or complication thereof which is responsive to, or which is prevented by, a polypeptide therapeutic agent via oral, orogastric, nasogastric, or intragastric administration routes. Further provided are compositions for use in such methods.

1. The name of the design product: intragastric administration device (rat). 2. The use of the design product: for intragastric administration to rats. 3. The design points of the design product: in shape. 4. The picture or photo that best shows the design points: perspective view 1.

The invention relates to the technical field of biology, in particular to application of lactobacillus johnsonii in colorectal tumor. According to the application, low-abundance lactobacillus johnsonii is used as a biomarker of colorectal tumors, and the abundance ratio of the low-abundance lactobacillus johnsonii to normal-abundance lactobacillus johnsonii is smaller than or equal to 0.9. Based on a large number of experiments in the early stage, the abundance of lactobacillus johnsonii in the intestinal tract of a patient with colorectal tumor shows a significant reduction trend; in addition, the abundance of the lactobacillus johnsonii in the intestinal tract of the patient with colorectal tumor is highly positively correlated with the beneficial bacterium bacteroides simplex in the intestinal tract and is negatively correlated with harmful bacteria in the intestinal tract; in addition, lactobacillus johnsonii is used for intragastric administration, and the number and the volume of tumors of a mouse with colorectal tumors are obviously reduced, so that the lactobacillus johnsonii can be used as a biomarker of the colorectal tumors, and the blank of application of the lactobacillus johnsonii in the aspect of the colorectal tumors in the prior art is filled.

The invention discloses a method for constructing an alcoholic liver injury animal model and application, and belongs to the technical field of gene editing. The technical problem to be solved by the invention is how to construct the alcoholic liver injury animal model. The method for constructing the alcoholic liver injury animal model disclosed by the invention comprises the following steps: knocking out an animal Cfhr3 gene to obtain a Cfhr3 gene knockout animal; and performing intragastric administration on the Cfhr3 gene knockout animal with ethanol or an aqueous solution thereof to obtain the alcoholic liver injury animal model. The animal model constructed by the method shows that after ethanol gavage, liver tissue has balloon-like change, obvious fat vacuoles appear, hepatic cord structures disappear, hepatocytes are swollen, the liver tissue is damaged, the liver index is improved, and the content of glutamic-pyruvic transaminase and glucose in blood is increased. The alcoholic liver injury animal model is successfully obtained.